AGILENT TECHNOLOGIES, INC. (A) FY2025 Q1 P&L / Income Statement

Revenue by Business Segment by Geography

2024-11-01 to 2025-01-31

Swipe to see the full flow
AGILENT TECHNOLOGIES, INC. (A) FY2025 Q1 P&L / Income StatementIncome statement for 2024-11-01 through 2025-01-31. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETLife Sciences and Diagnostics Markets - AmericasAgilent CrossLab - AmericasAgilent CrossLab - Asia PacificLife Sciences and Diagnostics Markets - EuropeAgilent CrossLab - EuropeApplied Markets - Asia PacificLife Sciences and Diagnostics Markets - Asia PacificApplied Markets - AmericasApplied Markets - EuropeNet revenueGross profit (calculated)Cost of revenueIncome from operationsOperating expenses (calculated)Selling, general and administrativeResearch and developmentIncome before taxesOther income (expense), net (calculated)Net incomeProvision for income taxesGross profit (calculated)Gross profit(calculated)$899.00 MNet revenueNet revenue$1.68 BIncome from operationsIncome from operations$376.00 MIncome before taxesIncome before taxes$367.00 MLife Sciences and Diagnostics Markets - AmericasLife Sciences and DiagnosticsMarkets - Americas$312.00 MNet incomeNet income$318.00 MAgilent CrossLab - AmericasAgilent CrossLab - Americas$261.00 MOperating expenses (calculated)Operating expenses(calculated)$523.00 MProvision for income taxesProvision forincome taxes$49.00 MAgilent CrossLab - Asia PacificAgilent CrossLab - Asia Pacific$247.00 MOther income (expense), net (calculated)Other income,net (calculated)−$9.00 MSelling, general and administrativeSelling, general and administrative$410.00 MCost of revenueCost of revenue$782.00 MLife Sciences and Diagnostics Markets - EuropeLife Sciences andDiagnostics Markets - Europe$190.00 MResearch and developmentResearch and development$113.00 MAgilent CrossLab - EuropeAgilent CrossLab - Europe$188.00 MApplied Markets - Asia PacificApplied Markets - Asia Pacific$157.00 MLife Sciences and Diagnostics Markets - Asia PacificLife Sciences and DiagnosticsMarkets - Asia Pacific$145.00 MApplied Markets - AmericasApplied Markets - Americas$96.00 MApplied Markets - EuropeApplied Markets - Europe$85.00 M
Chart details

AGILENT TECHNOLOGIES, INC. (A) FY2025 Q1 P&L / Income Statement

Income statement for 2024-11-01 through 2025-01-31. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenue
1,681,000,000 US dollars
Cost of revenue
782,000,000 US dollars
Gross profit (calculated)
899,000,000 US dollars
Operating expenses (calculated)
523,000,000 US dollars
Income from operations
376,000,000 US dollars
Other income (expense), net (calculated)
negative 9,000,000 US dollars
Income before taxes
367,000,000 US dollars
Provision for income taxes
49,000,000 US dollars
Net income
318,000,000 US dollars
Agilent CrossLab - Americas
261,000,000 US dollars
Agilent CrossLab - Asia Pacific
247,000,000 US dollars
Agilent CrossLab - Europe
188,000,000 US dollars
Applied Markets - Americas
96,000,000 US dollars
Applied Markets - Asia Pacific
157,000,000 US dollars
Applied Markets - Europe
85,000,000 US dollars
Life Sciences and Diagnostics Markets - Americas
312,000,000 US dollars
Life Sciences and Diagnostics Markets - Asia Pacific
145,000,000 US dollars
Life Sciences and Diagnostics Markets - Europe
190,000,000 US dollars
Research and development
113,000,000 US dollars
Selling, general and administrative
410,000,000 US dollars

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
AGILENT TECHNOLOGIES, INC. (A) FY2025 Q1 Revenue by Business Segment by Geography Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

53.5%

Gross profit / revenue

Operating margin

22.4%

Operating profit / revenue

Cash conversion

135.5%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!